source
- Milestone Pharmaceuticals trims 20% workforce after FDA approval as Q3 sales reach $1 millionMilestone Pharmaceuticals announced it is reducing its headcount by about one‑fifth following the recent FDA approval of its heart‑arrhythmia therapy. The cut affects roughly 20% of the company’s s…
- AstraZeneca withdraws EU filing for monoclonal antibody targeting amyloidosis subsetAstraZeneca has announced that it is pulling its European marketing application for a monoclonal antibody intended for a specific subgroup of amyloidosis patients. The decision follows earlier fail…